FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2120951883> ?p ?o ?g. }

• W2120951883 endingPage "66" @default.
• W2120951883 startingPage "357" @default.
• W2120951883 abstract "The time-dependent (5 min-72 h) localization of 3 radiolabeled anti-melanoma monoclonal antibodies (MAbs 436, IND1, and 9.2.27) was studied in paired label experiments in small (4-12 mg) s.c. human melanoma xenografts (SK-MEL-2 and M21) in athymic nude mice. MAb 436 recognizes a Mr 125,000 cell surface melanoma-associated glycoprotein antigen (125 kDa-MAA); MAbs IND1 and 9.2.27 recognize a high molecular weight melanoma-associated antigen, but with equilibrium association constants differing by 2 orders of magnitude (10(8)-10(10) M-1). The two tumors were found to differ in their antigen expression levels and in both interstitial and vascular volumes. Accumulation of MAbs in both tumors was determined primarily by antigen expression levels and also by physiological factors such as vascular permeability and vascular volume; at the dose administered (20 micrograms/mouse), differences in MAb affinity among specific MAbs had minimal effect on accumulation. Quantitative flow cytometry measurements showed that antigen expression in vivo differed from that of cultured tumor cells. In vivo, expression of the Mr 125,000 MAA decreased by a factor of about 2.5 in both tumors. In contrast, the in vivo expression of the high molecular weight MAA decreased in M21 tumors but increased by 2.0-3.5-fold in SK-MEL-2 tumors. Data were analyzed using a three-compartment pharmacokinetic model (C. Sung et al., Cancer Res., 52:377-384, 1992) to provide plasma-to-tissue transport constants (k), the interstitial fluid flow rate (L), and estimates of the in vivo interstitial MAb binding site concentration (B0). For all MAbs, the plasma-to-tissue transport constants were consistently greater for M21 tumors (0.44-0.85 microliter/min/g) than for SK-MEL-2 tumors (0.28-0.66 microliter/min/g), and values of k for both tumors were approximately 1 order of magnitude greater than those for skeletal muscle (0.06-0.08 microliter/min/g). The model-estimated binding site concentration of melanoma-specific antibodies was 15-70 times lower than that predicted by experimental measurements of tumor antigen concentrations. Factors that may contribute to this discrepancy include inaccessibility of tumor cell binding sites to MAb and MAb catabolism. In summary, these results indicate that, for the MAb dose used in this study, variables pertaining to the tumor target (i.e., antigen expression levels, vascular volume, and vascular permeability) are the most important for determining MAb accumulation in tumors." @default.
• W2120951883 created "2016-06-24" @default.
• W2120951883 creator A5007150862 @default.
• W2120951883 creator A5008085561 @default.
• W2120951883 creator A5011962400 @default.
• W2120951883 creator A5045720971 @default.
• W2120951883 creator A5055658784 @default.
• W2120951883 creator A5058290100 @default.
• W2120951883 creator A5062637916 @default.
• W2120951883 creator A5065599106 @default.
• W2120951883 date "1992-01-15" @default.
• W2120951883 modified "2023-09-23" @default.
• W2120951883 title "A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels." @default.
• W2120951883 cites W1531648615 @default.
• W2120951883 cites W1534229576 @default.
• W2120951883 cites W1554187358 @default.
• W2120951883 cites W1593638182 @default.
• W2120951883 cites W1649529648 @default.
• W2120951883 cites W175938947 @default.
• W2120951883 cites W1810166418 @default.
• W2120951883 cites W1831517994 @default.
• W2120951883 cites W1843966557 @default.
• W2120951883 cites W1938637922 @default.
• W2120951883 cites W1958434205 @default.
• W2120951883 cites W1966795694 @default.
• W2120951883 cites W1973544892 @default.
• W2120951883 cites W1974392214 @default.
• W2120951883 cites W1975135473 @default.
• W2120951883 cites W1984883977 @default.
• W2120951883 cites W1999058050 @default.
• W2120951883 cites W2002820450 @default.
• W2120951883 cites W2007905457 @default.
• W2120951883 cites W2013738563 @default.
• W2120951883 cites W2016194947 @default.
• W2120951883 cites W2017652518 @default.
• W2120951883 cites W2019783067 @default.
• W2120951883 cites W2020094242 @default.
• W2120951883 cites W2027565419 @default.
• W2120951883 cites W2028345930 @default.
• W2120951883 cites W2031928907 @default.
• W2120951883 cites W2058426435 @default.
• W2120951883 cites W2075120823 @default.
• W2120951883 cites W2080580789 @default.
• W2120951883 cites W2086882533 @default.
• W2120951883 cites W2102119006 @default.
• W2120951883 cites W2110962921 @default.
• W2120951883 cites W2116175718 @default.
• W2120951883 cites W2122024851 @default.
• W2120951883 cites W2132059239 @default.
• W2120951883 cites W2150022505 @default.
• W2120951883 cites W2161816757 @default.
• W2120951883 cites W2163308073 @default.
• W2120951883 cites W2250352069 @default.
• W2120951883 cites W2320701394 @default.
• W2120951883 cites W2338107399 @default.
• W2120951883 cites W2480800149 @default.
• W2120951883 cites W567786599 @default.
• W2120951883 cites W2124221123 @default.
• W2120951883 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1728407" @default.
• W2120951883 hasPublicationYear "1992" @default.
• W2120951883 type Work @default.
• W2120951883 sameAs 2120951883 @default.
• W2120951883 citedByCount "37" @default.
• W2120951883 countsByYear W21209518832015 @default.
• W2120951883 countsByYear W21209518832018 @default.
• W2120951883 countsByYear W21209518832022 @default.
• W2120951883 crossrefType "journal-article" @default.
• W2120951883 hasAuthorship W2120951883A5007150862 @default.
• W2120951883 hasAuthorship W2120951883A5008085561 @default.
• W2120951883 hasAuthorship W2120951883A5011962400 @default.
• W2120951883 hasAuthorship W2120951883A5045720971 @default.
• W2120951883 hasAuthorship W2120951883A5055658784 @default.
• W2120951883 hasAuthorship W2120951883A5058290100 @default.
• W2120951883 hasAuthorship W2120951883A5062637916 @default.
• W2120951883 hasAuthorship W2120951883A5065599106 @default.
• W2120951883 hasConcept C142724271 @default.
• W2120951883 hasConcept C147483822 @default.
• W2120951883 hasConcept C150903083 @default.
• W2120951883 hasConcept C153911025 @default.
• W2120951883 hasConcept C159654299 @default.
• W2120951883 hasConcept C185592680 @default.
• W2120951883 hasConcept C203014093 @default.
• W2120951883 hasConcept C207001950 @default.
• W2120951883 hasConcept C2777658100 @default.
• W2120951883 hasConcept C502942594 @default.
• W2120951883 hasConcept C542903549 @default.
• W2120951883 hasConcept C553184892 @default.
• W2120951883 hasConcept C71924100 @default.
• W2120951883 hasConcept C86803240 @default.
• W2120951883 hasConceptScore W2120951883C142724271 @default.
• W2120951883 hasConceptScore W2120951883C147483822 @default.
• W2120951883 hasConceptScore W2120951883C150903083 @default.
• W2120951883 hasConceptScore W2120951883C153911025 @default.
• W2120951883 hasConceptScore W2120951883C159654299 @default.
• W2120951883 hasConceptScore W2120951883C185592680 @default.
• W2120951883 hasConceptScore W2120951883C203014093 @default.
• W2120951883 hasConceptScore W2120951883C207001950 @default.
• W2120951883 hasConceptScore W2120951883C2777658100 @default.

• next